What is TELO's earnings growth forecast for 2026-2026?
(NASDAQ: TELO) Telomir Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of N/A, and while it is not forecast to beat the US market's average forecast earnings growth rate of N/A.
Telomir Pharmaceuticals's earnings in 2026 is -$11,250,385.
In 2026, TELO is forecast to generate -$9,819,205 in earnings, with the lowest earnings forecast at -$9,434,138 and the highest earnings forecast at -$10,108,005.
What is TELO's revenue growth forecast for 2026-2026?
(NASDAQ: TELO) Telomir Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of N/A, and while it is not forecast to beat the US market's average forecast revenue growth rate of N/A.
Telomir Pharmaceuticals's revenue in 2026 is $0.
In 2026, TELO is forecast to generate $52,602,886 in revenue, with the lowest revenue forecast at $50,540,027 and the highest revenue forecast at $54,150,029.
What is TELO's forecast return on assets (ROA) for 2026-2026?
(NASDAQ: TELO) forecast ROA is -132.65%, which is lower than the forecast US Biotechnology industry average of 18.25%.
What is TELO's Earnings Per Share (EPS) forecast for 2026-2026?
(NASDAQ: TELO) Telomir Pharmaceuticals's current Earnings Per Share (EPS) is -$0.37. In 2026, TELO's EPS is forecast to hit -$0.29 (min: -$0.27, max: -$0.29).
What is TELO's forecast return on equity (ROE) for 2026-2026?
(NASDAQ: TELO) forecast ROE is -140.69%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.